A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides

• Main Authors: Xiaojie Wu (Author), Jicheng Yu (Author), Beikang Ge (Author), Jeffrey Wang (Author), Xiaoran Han (Author), Chunye Zhang (Author), Xiaomeng Mao (Author), Hindu Kalluru (Author), Candace Bramson (Author), Steven G. Terra (Author), Jing Liu (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Vupanorsen is a GalNAc3-conjugated antisense oligonucleotide targeting angiopoietin-like 3 (ANGPTL3) mRNA shown to reduce atherogenic lipoproteins in individuals with dyslipidemia. Objectives The aim of this study was to satisfy Chinese regulatory requirements and support ethnic...